主要研究目的：研究空腹/餐后状态下口服受试制剂精氨酸培哚普利片（江西施美药业股份有限公司生产）与参比制剂精氨酸培哚普利片（COVERSYL®，Les Laboratoires Servier生产）在中国健康成年受试者体内的药代动力学特征，评价空腹/餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂精氨酸培哚普利片和参比制剂精氨酸培哚普利片（COVERSYL®）在中国健康成年受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation Perindopril Arginine Tablets (produced by Jiangxi Shimei Pharmaceutical Co., Ltd.) and the reference preparation Perindopril Arginine Tablets (COVERSYL®, produced by Les Laboratoires Servier) in healthy Chinese adult subjects in the fasting/fed state, and to evaluate the bioequivalence of the two preparations in the fasting/fed state. Secondary purpose of the study is to evaluate the safety of the test preparation Perindopril Arginine Tablets and the reference preparation Perindopril Arginine Tablets (COVERSYL®) in healthy Chinese adult subjects.

Start Date26 Feb 2024

Sponsor / Collaborator

Jiangxi Shimei Pharmaceutical Co., Ltd.

CTR20233406

/ CompletedNot Applicable

精氨酸培哚普利片人体生物等效性研究

[Translation] Study on the bioequivalence of arginine perindopril tablets in healthy volunteers

本试验旨在研究单次空腹和餐后口服石家庄四药有限公司研制、生产的精氨酸培哚普利片（10mg）的药代动力学特征；以Les Laboratoires Servier持证的精氨酸培哚普利片（Coversyl，10mg）为参比制剂，比较两制剂中药动学参数，评价两制剂的人体生物等效性，并观察两制剂在健康受试者中的安全性。

[Translation]

This study aims to study the pharmacokinetic characteristics of a single fasting and postprandial oral administration of arginine perindopril tablets (10 mg) developed and produced by Shijiazhuang Siyao Co., Ltd.; using arginine perindopril tablets (Coversyl, 10 mg) certified by Les Laboratoires Servier as the reference preparation, compare the pharmacokinetic parameters of the two preparations, evaluate the human bioequivalence of the two preparations, and observe the safety of the two preparations in healthy subjects.

Start Date23 Nov 2023

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

CTR20230504

/ CompletedNot Applicable

一项单中心、随机、开放、单次给药、两制剂、两周期交叉设计研究评价杭州仟源保灵药业有限公司的精氨酸培哚普利片与Les Laboratoires Servier的精氨酸培哚普利片在健康受试者中的空腹和餐后状态下的生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose, two-dose, two-period crossover design study to evaluate the bioequivalence of arginine perindopril tablets from Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. and arginine perindopril tablets from Les Laboratoires Servier in healthy subjects under fasting and fed conditions

主要研究目的：评价杭州仟源保灵药业有限公司的精氨酸培哚普利片与Les Laboratoires Servier的精氨酸培哚普利片空腹和餐后单次口服给药后在健康人群中的生物等效性。次要研究目的：评价受试制剂和参比制剂在健康人群中的安全性。

[Translation]

Primary study objective: To evaluate the bioequivalence of the arginine perindopril tablets of Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. and the arginine perindopril tablets of Les Laboratoires Servier in healthy subjects after single oral administration on an empty stomach and after meals. Secondary study objective: To evaluate the safety of the test preparation and the reference preparation in healthy subjects.

Start Date13 Feb 2023

Sponsor / Collaborator

Hangzhou QIANYUAN Pollen Pharmaceutical Co., Ltd.

100 Clinical Results associated with Perindopril Arginine

100 Translational Medicine associated with Perindopril Arginine

100 Patents (Medical) associated with Perindopril Arginine

2,354

Literatures (Medical) associated with Perindopril Arginine

01 Feb 2026·Cardiovascular Toxicology

Role of Perindopril in Mitigating Doxorubicin’s Vascular Toxicity in a Rat Model

Article

Author: Šůstková, Lucie ; Hložková, Jana ; Nádeníček, Jaroslav ; Nováková, Marie ; Smutná, Jindra ; Studenik, Christian ; Marhefka, Filip ; Hendrych, Michal ; Stračina, Tibor ; Scheer, Peter ; Paulová, Hana ; Marada, Anna

Abstract:

Doxorubicin (DOX), a widely used anthracycline in cancer therapy, is associated with significant cardiovascular toxicity. While its cardiotoxic effects are well documented, the mechanisms and prevention of DOX-induced vascular toxicity remain insufficiently explored. Angiotensin-converting enzyme inhibitors (ACEIs), such as perindopril (PER), are commonly used in cardiovascular disease management and may offer vascular protection during chemotherapy. Female ovariectomized Wistar rats were treated with i.v. DOX and/or p.o. PER over five weeks. Cardiac and vascular function were assessed using high-frequency ultrasound and ECG. Vascular reactivity was evaluated in isolated aortal rings using phenylephrine (PE), acetylcholine (ACh), L-N-Nitro arginine methyl ester hydrochloride (L-NAME), and verapamil (VER). Oxidative stress was assessed via plasma 4-hydroxy-2-nonenal (4-HNE) levels, and structural changes were monitored through intima-media thickness (IMT) measurements. DOX administration significantly impaired vascular reactivity, as evidenced by increased contractile responses to PE and reduced endothelium-dependent relaxation. These functional alterations were accompanied by elevated plasma 4-HNE levels, indicating enhanced oxidative stress. Co-treatment with PER preserved vascular responsiveness, reduced contractile tension, and significantly lowered 4-HNE concentrations. Structurally, IMT increased in control and PER-only groups, likely due to post-ovariectomy remodelling, while DOX-treated groups showed no IMT progression. PER co-treatment appeared to stabilize IMT values. PER mitigates DOX-induced vascular toxicity, likely through endothelial protection and reduction of oxidative stress. These findings support the potential use of ACEIs as prophylactic agents in patients undergoing anthracycline-based chemotherapy and highlight the need for further translational studies in cardio-oncology. Graphical Abstract

31 Dec 2025·BLOOD PRESSURE

A systematic review of commencing full-dose antihypertensives in newly diagnosed hypertension

Review

Author: Karavadra, Babu ; Shantsila, Alena ; Lip, Gregory Y.H. ; Shantsila, Eduard ; d′Elia, Alexander

BACKGROUND:

Hypertension is the UK's most common treatable cause of mortality and morbidity, including cardiovascular disease (CVD), renal disease and dementia.

OBJECTIVE:

This systematic review has explored the efficacy and safety of commencing full-dose antihypertensive treatment in individuals with essential hypertension.

METHOD:

Method16 randomised controlled trials (RCTs) were eligible for inclusion, with some RCTs assessing more than one treatment. The review assessed commonly used antihypertensive drugs (perindopril 8 mg, ramipril 10 mg, amlodipine 10 mg, losartan 100 mg, irbesartan 300 mg, candesartan 16 mg and candesartan 32 mg) compared to low starting doses or placebo RCTs. Eligible studies included 12 RCTs that compared full vs low doses and 19 RCTs that compared full starting doses vs placebo. The primary outcome was the difference in blood pressure reduction compared to controls (reported or calculated). ResultsUsing full doses compared to low doses led to better BP reduction (overall, 3.9/2.2 mmHg lower achieved BP) without an increase in adverse effects. This notion is supported by the changes achieved with full-dose treatment initiation compared to placebo (average over all studies: 11.4 [4.4]/6.5 [2.9] mmHg).

CONCLUSIONS:

This review indicates that initiating full-dose antihypertensives for essential hypertension may be beneficial and safe. The available data are limited, and further RCTs are required to assess this in specific patient groups to assess safety and efficac.

19 Dec 2025·Cureus Journal of Medical Science

Intestinal Angioedema Induced by Angiotensin-Converting Enzyme Inhibitors: A Diagnosis of Exclusion

Article

Author: Sá, Sara ; Pera, Rita ; Gradinaru, Andrei ; Lagarteira, João ; Figueiredo, Ana

Angiotensin-converting enzyme inhibitor (ACEI)-induced intestinal angioedema is a rare and frequently underdiagnosed condition, often presenting with nonspecific gastrointestinal symptoms that can mimic inflammatory, infectious, or neoplastic diseases. We report the case of a 42-year-old female patient who recently started perindopril (an ACEI) for uncontrolled hypertension and developed recurrent abdominal pain and diarrhea. Extensive laboratory and imaging workup, complemented by endoscopic and histological evaluations, did not identify any alternative etiology. Symptoms resolved completely after discontinuation of perindopril, confirming ACEI-induced intestinal angioedema. Early recognition of this entity is essential to avoid invasive procedures and ensure complete resolution with simple drug discontinuation.

News (Medical) associated with Perindopril Arginine

29 Aug 2025

·www.einpresswire.com

January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Addyi (flibanserin) Drug hypersensitivity The "Contraindications", "Warnings and Precautions", "Adverse Reactions", and "Medication Guide" sections of the labeling were updated in September 2021 to include hypersensitivity reactions. Addyi labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua (insulin glargine and lixisenatide) Trulicity (dulaglutide) Victoza (liraglutide) Xultophy (insulin degludec and liraglutide) Drug-induced liver injury The "Adverse Reactions" section of the liraglutide and dulaglutide labeling was updated in June 2022 to include information about elevations of liver enzymes. Example: Trulicity labeling FDA determined that no action is necessary at the time for lixisenatide, exenatide, and semaglutide based on available information. Alcohol-based hand sanitizers Exposure via inhalation FDA determined that no action is necessary at the time based on available information. A FDA Drug Safety Communication was issued on June 16, 2021. Amlodipine and Levamlodipine Products Azor (amlodipine and olmesartan medoxomil ) Caduet (amlodipine besylate and atorvastatin calcium) Conjupri (levamlodipine maleate) Consensi (amlodipine besylate and celecoxib) Exforge (amlodipine and valsartan) Exforge HCT (amlodipine/valsartan and hydrochlorothiazide) Lotrel (amlodipine besylate and benazepril hydrochloride) Katerzia (amlodipine benzoate) Norvasc (amlodipine besylate) Prestalia (amlodipine besylate and perindopril arginine) Tribenzor (amlodipine besylate/olmesartan medoxomil and hydrochlorothiazide) Twynsta (amlodipine and telmisartan) Non-cardiogenic pulmonary edema FDA determined that no action is necessary at the time based on available information. Avonex (interferon beta-1a) Betaseron (interferon beta-1b) Extavia (interferon beta-1b) Plegridy (pegylated interferon beta-1a) Rebif (interferon beta-1a) Injection site abscess FDA is evaluating the need for regulatory action. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Scleroderma FDA determined that no action is necessary at the time based on available information. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Cholangitis sclerosing The "Adverse Reactions" section of the Keytruda (pembrolizumab) labeling was updated in August 2021 to include sclerosing cholangitis. Example: Keytruda labeling FDA determined that no action is necessary at the time for Bavencio (avelumab), Imfinzi (durvalumab), Libtayo (cemiplimab-rwlc), Opdivo (nivolumab), and Tecentriq (atezolizumab) based on available information. Chloroquine Generic products containing chloroquine Phospholipidosis The “Warnings” section of the labeling was updated in May 2022 to include information about phospholipidosis. Eliquis (apixaban) Pradaxa (dabigatran etexilate mesylate) Savaysa (edoxaban tosylate) Xarelto (ribaroxaban) Generic products containing dabigatran etexilate mesylate Generic products containing ribaroxaban Menorrhagia The “Use in Specific Populations” section was updated April 2021 to add language to describe the risk of clinically significant uterine bleeding in females of reproductive potential. Eliquis label Pradaxa label Savaysa label Xarelto label Depakote (divalproex sodium) Depakote ER (divalproex sodium) Stavzor (valproic acid) Generic products containing divalproex sodium Generic products containing valproic acid Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated in November 2021 to include tubulointerstitial nephritis. Example: Depakote labeling Dupixent (dupilumab) Alopecias FDA is evaluating the need for regulatory action. H.P. Acthar Gel (corticotropin) Anaphylactic and anaphylactoid responses The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include anaphylaxis. Acthar Gel labeling H.P. Acthar Gel (corticotropin) Cardiac arrhythmias The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include atrial fibrillations and palpitations. Acthar Gel labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Verzenio (abemaciclib) Second primary malignancy FDA determined that no action is necessary at the time based on available information. Lynparza (olaparib) Drug-induced liver injury FDA determined that no action is necessary at the time based on available information. Ocrevus (ocrelizumab) Autoimmune colitis The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Medication Guide" sections of the labeling were updated in August 2022 to include colitis. Ocrevus labeling Poteligeo (mogamulizumab-kpkc) Acute kidney injury The "Warnings and Precautions" section of the labeling was updated in March 2022 to include glomerulonephritis. Poteligeo labeling Ravicti (glycerol phenylbutyrate) Product labeling issue regarding stability and instructions for administration The container label, carton label, "Medication Guide", and sections of the Prescribing Information ("Dosage and Administration" and "Patient Counseling Information") were updated in September 2021 to enhance the instructions for administration. Ravicti labeling Spravato (esketamine) Hypertensive crisis FDA determined that no action is necessary at the time based on available information. Tremfya (guselkumab) Device use errors resulting in possible missed or partial doses The Tremfya One Press Instructions for Use (IFU) and carton labeling was updated in June 2023 to mitigate medication errors, such as underdose or no dose delivered. Tremfya labeling Trulance (plecanatide) Drug hypersensitivity The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include skin itching, hives, and rash. Trulance Label Trulance (plecanatide) Vomiting The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include vomiting. Trulance Label Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

05 Sep 2023

·www.biospace.com

Pharmascience Canada launches a new generic drug to treat hypertension

[05-September-2023] MONTREAL, Sept. 5, 2023 /CNW/ - pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine / indapamide) is used in adults for the initial treatment of mild to moderate essential hypertension (high blood pressure). pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine/ indapamide) are a combination of perindopril erbumine, an angiotensin converting enzyme (ACE) inhibitor, and indapamide, a chlorosulphamoyl diuretic. These two active ingredients act synergistically to lower blood pressure in hypertensive patients of all ages. pms-PERINDOPRIL-INDAPAMIDE comes in the following dosage forms: Tablets of 2 mg perindopril erbumine/ 0.625 mg indapamide. Tablets of 4 mg perindopril erbumine/ 1.25 mg indapamide. Tablets of 8 mg perindopril erbumine/ 2.5 mg indapamide. pms-PERINDOPRIL-INDAPAMIDE is a generic equivalent to Coversyl® Plus, Coversyl® Plus LD and Coversyl® Plus HD and has the same safety and efficacy as Coversyl®. pms-PERINDOPRIL-INDAPAMIDE tablets are offered at a lower price than brand-name products. "The Pharmascience team is happy to bring to market pms-Perindopril-Indapamide used for the initial treatment of high blood pressure. The availability of pms-Perindopril-Indapamide gives every Canadian an affordable and important treatment option! At Pharmascience, we take tremendous pride in our locally produced medicines and will continue to focus on growing our portfolio with quality medications needed for all Canadians!" - mentioned Mike Dutton, Vice President, and General Manager of Pharmascience Canada. ABOUT PHARMASCIENCE INC. Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 50th among Canada's top 100 Research & Development (R&D) investors in 2022, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada. Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2023, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada's Top Employers for Young People as part of Canada's Top 100 Employers. Pharmascience is now certified as a Great Place to Work for a second year in a row. For product information, please contact Pharmascience's Medical Information Department at 1-888-550-6060. Coversyl® Plus, Coversyl® Plus LD and Coversyl® Plus HD are registered trademark owned by Servier Canada Inc. SOURCE Pharmascience Inc.

Drug Approval

100 Deals associated with Perindopril Arginine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Perindopril Arginine	C09AA04	DB00790

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	China	Les Laboratoires Servier SAS	17 Oct 2014
Coronary Disease	Australia	Servier Laboratories (Australia) Pty Ltd.	08 Jun 2005
Heart Failure	Australia	Servier Laboratories (Australia) Pty Ltd.	08 Jun 2005
Hypertension	Australia	Servier Laboratories (Australia) Pty Ltd.	08 Jun 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01118520 (AARDVARK, CTgov)	Phase 2	Aortic Aneurysm, Abdominal	224	perindopril arginine (Perindopril)	rqbjqtmamh(pdmuclawhe) = bsabyevvsg mmifjvbaks (wcicewrazo, 0.02) View more	-	26 Jan 2021
				amlodipine 5mgs (Amlodipine)	rqbjqtmamh(pdmuclawhe) = xiojxffdqi mmifjvbaks (wcicewrazo, 0.02) View more
NCT01669434 (CTgov)	Phase 4	Hypotension	291	LISINOPRIL+Captopril+ENALAPRILAT+BENAZEPRIL HYDROCHLORIDE+PERINDOPRIL ERBUMINE+RAMIPRIL+QUINAPRIL HYDROCHLORIDE+Enalapril Maleate+Perindopril Arginine+FOSINOPRIL SODIUM+TRANDOLAPRIL+MOEXIPRIL HYDROCHLORIDE (ACEI Omission)	qytgysoiwq = xtalfyeuhb erdzhmzhun (cwifrggoim, ymiwrylqyu - qrmxccfhlb) View more	-	11 Dec 2017
				ACEI continuation (ACEI Continuation)	qytgysoiwq = grlhsskcry erdzhmzhun (cwifrggoim, irugcjluqz - deeuobqjje) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis